Rezdiffra (Resmetirom) Adolescent (12 to 17) Dosing: What Clinicians and Parents Need to Know

Direct answer

Resmetirom has no FDA-approved use, no established dose, and no published pharmacokinetic or safety data in patients under 18. The 80 mg / 100 mg weight-based adult regimen was derived from adult exposure-response data and cannot be assumed to transfer safely to a growing adolescent, because thyroid hormone signaling, hepatic enzyme maturation, and body composition all change during puberty. Until a dedicated pediatric pharmacokinetic study exists, any adolescent use should be considered strictly investigational, ideally within a clinical trial, and if pursued off-label, only under a pediatric hepatologist with a predefined monitoring protocol.

What resmetirom is, in plain terms

Resmetirom (Rezdiffra) is an oral, once-daily, small-molecule agonist selective for thyroid hormone receptor beta (THR-beta), a receptor concentrated in liver cells that helps regulate lipid metabolism and hepatic fat clearance. It is not a GLP-1 receptor agonist, not obeticholic acid, and not the same class as lanifibranor, all of which are sometimes discussed alongside it for fatty liver disease. It is approved in adults for metabolic dysfunction-associated steatohepatitis (MASH, formerly called NASH) with non-cirrhotic liver disease and fibrosis stage F2 or F3, based on the FDA's accelerated approval pathway in March 2024 (verify current label status at the FDA link below, since accelerated approvals can be modified as confirmatory trial data mature).

Pediatric fatty liver disease is a real and growing problem, and that is precisely why the absence of pediatric dosing data matters. Obese adolescents referred for liver evaluation include a meaningful subset with biopsy-confirmed MASH, and there is currently no drug approved specifically for that population. Resmetirom's adult approval has generated interest in whether it could eventually fill that gap, but interest is not evidence.

What the FDA label actually says about adolescents

The current prescribing information limits the approved population to adults with non-cirrhotic MASH and fibrosis staged F2 or F3, using a weight-based split (80 mg under 100 kg, 100 mg at or above 100 kg) taken orally with food. The label does not provide a pediatric dosing table. It states that safety and effectiveness have not been established in pediatric patients. That single sentence is the entirety of the pediatric-specific guidance in the current label, and it should be read as the FDA declining to make a recommendation rather than as a soft yes.

Reference: Rezdiffra prescribing information, FDA (verify current label version and revision date before relying on any specific dosing detail, since labels can be amended).

Why pediatric data do not exist yet

New drugs are typically studied in adults first, and pediatric studies often follow under the Pediatric Research Equity Act (PREA), which can require pediatric studies for a condition that also affects children, subject to deferrals and exemptions. As of this review, no adolescent resmetirom trial has been registered publicly, and the manufacturer has not disclosed a pediatric development timeline. That absence of data is not itself evidence of safety or of harm. It means the risk-benefit tradeoff in adolescents has not been formally characterized, which is a materially different situation from a drug that has been studied in children and found to carry low risk.

Reference: FDA, Pediatric Research Equity Act (PREA)

Why adult weight-based dosing does not simply scale down

Weight-based extrapolation is common in pediatrics, but it depends on assumptions that do not clearly hold here.

Growth plates remain open through adolescence, and thyroid hormone signaling participates in skeletal maturation. Resmetirom's selectivity for THR-beta over THR-alpha is the basis for its adult cardiac and bone safety profile, but growth-plate cartilage expresses some THR-beta as well, and no study has measured whether adolescent exposure affects bone age or final height. This is a plausible, biologically grounded concern, not an established one; it needs a dedicated pediatric safety study to resolve either way, and clinicians should say so plainly rather than reassuring families based on the adult data alone.

Hepatic drug metabolism also changes across puberty, and resmetirom is metabolized primarily through hepatic pathways that mature during adolescence. A dose that produces a given exposure in a middle-aged adult with a certain body weight will not necessarily produce the same exposure in a 14-year-old at the same weight, because enzyme activity, protein binding, and body composition differ. Population pharmacokinetic modeling in an adolescent cohort, not simple weight scaling, is the step that would need to happen before any adolescent dose could be proposed with confidence. That work has not been done.

The strongest evidence-anchored statement on this page

Resmetirom (Rezdiffra) carries an FDA-approved adult dosing regimen (80 mg or 100 mg daily by weight) for non-cirrhotic MASH with fibrosis stage F2 or F3, but as of this review it has no approved pediatric indication, no published adolescent pharmacokinetic or safety data, and no registered trial in patients under 18. The label states plainly that safety and effectiveness have not been established in pediatric patients. Any dosing decision for a 12 to 17 year old is therefore off-label and individualized, not a scaled-down version of the adult regimen, and should not be treated as routine care outside specialist oversight.

What guideline bodies currently recommend for adolescent fatty liver disease

Published pediatric fatty liver disease guidance from gastroenterology and hepatology societies has generally recommended lifestyle intervention (diet and physical activity) as first-line treatment, with vitamin E considered in biopsy-proven pediatric NASH in children older than roughly 8 years, based on older pediatric trial data. No pharmacologic agent beyond vitamin E currently carries a guideline-level recommendation for pediatric MASH or NASH. GLP-1 receptor agonists such as semaglutide are approved for adolescent obesity (age 12 and older) and produce meaningful weight loss in that population, which is associated with improvement in liver fat on imaging, though this is an indirect benefit rather than a MASH-specific approval. Readers should verify the current version of any pediatric NAFLD/NASH guideline directly, since recommendations are periodically updated.

If off-label use is being considered: a clinician discussion and monitoring framework

This framework distinguishes what the FDA label supports, what would need individualized judgment, and where escalation or stopping is warranted. It does not replace a specialist's judgment and is not a protocol to be followed without a pediatric hepatologist directly involved.

Before any dose is given

During treatment, if off-label use proceeds

Where label guidance ends and individualized judgment begins

The FDA label supports dosing, monitoring intervals, and safety parameters only for adults. Everything above the dashed line between "label guidance" and "individualized care" in adolescent use, including starting dose, titration pace, and monitoring frequency, is extrapolated clinical judgment, not label-directed care. Families and clinicians should understand that a monitoring plan like the one above is a reasonable safety framework, not a validated protocol with demonstrated outcomes in adolescents.

What is established, what is plausible, and what is not established

Established: Resmetirom is FDA-approved for adults with non-cirrhotic MASH and fibrosis F2/F3, dosed by a 100 kg weight cutoff. Adult trial data show histological benefit over placebo at the group level. The label explicitly disclaims pediatric safety and efficacy.

Plausible but unproven: THR-beta selectivity may reduce (but has not been shown to eliminate) risk to growth plates and the thyroid axis in adolescents. Weight-based adult dosing might approximate a workable adolescent dose, but this has not been tested pharmacokinetically.

Not established: Any specific adolescent dose, the drug's effect on final adult height or bone maturation in this age group, its safety during active puberty, and its efficacy for pediatric MASH histology. No claim about adolescent outcomes should be treated as more than a hypothesis awaiting a dedicated trial.

Questions parents can ask a prescriber

If a clinician raises resmetirom for an adolescent, reasonable questions include: What evidence supports use in someone under 18, specifically? What is the monitoring plan for thyroid function, growth, and bone health, and how often will it happen? Has a lower-risk, better-evidenced option (lifestyle intervention, vitamin E for biopsy-proven NASH, or a GLP-1 agonist for coexisting obesity) been tried and reassessed first? Is there a registered clinical trial the adolescent could join instead of an off-label prescription?